BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics to present 10 posters, presentations at USHLT
- Buy Recommendation for United Therapeutics: Undervalued Potential in IPF Treatment with Tyvaso
- United Therapeutics price target lowered to $314 from $328 at BofA
- Positive Outlook for United Therapeutics Amidst Competitive Landscape and Growth Initiatives
- United Therapeutics Corp. Reports Record Revenue and Growth